Basic information Pharmacological action Application Safety Supplier Related

Vemakalant

Basic information Pharmacological action Application Safety Supplier Related

Vemakalant Basic information

Product Name:
Vemakalant
Synonyms:
  • Vemakalant
  • Vernakalant
  • Vernakalant Impurity B ((3S, 1'R, 2'R)-Isomer)
  • CS-419
  • (3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
  • VERNAKALANT;RSD1235;RSD 1235;RSD-1235
  • (3R)-1-[(1R,2R)-2-[2-(3,4-Dimethoxyphenyl)ethoxy]cyclohexyl]-3-pyrrolidinol
  • 3-Pyrrolidinol, 1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]-, (3R)-
CAS:
794466-70-9
MF:
C20H31NO4
MW:
349.46
Mol File:
794466-70-9.mol
More
Less

Vemakalant Chemical Properties

Boiling point:
479.0±45.0 °C(Predicted)
Density 
1.14±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO
form 
Powder
pka
14.79±0.20(Predicted)
More
Less

Vemakalant Usage And Synthesis

Pharmacological action

Venakaran works by blocking peak sodium currents by blocking overdrive-activated delayed rectifier currents (IKur). IKur, encoded by the Kv1.5 channel protein, is abundantly expressed in atrial myocytes, is the main current mediating atrial repolarization in humans, and is activated during atrial fibrillation. Venakalan inhibition of IKur can prolong the action potential duration of the atrium, thereby prolonging the atrial effective refractory period and slowing down atrial conduction, so as to shorten the time of atrial fibrillation and quickly achieve the effect of atrial fibrillation conversion.

Application

Venakalan is a mixed sodium/potassium channel blocker that selectively acts on atrial ion channels. It is more effective than amiodarone in the acute conversion of newly diagnosed atrial fibrillation and is used clinically to treat atrial fibrillation.

Description

Vernakalant is a potassium channel blocker that was approved in Europe in 2010 for treatment of atrial fibrillation (AF), a condition of cardiac arrhythmia in which the atria of the heart beat irregularly due to changes in cardiac ion channel function and distribution. Vernakalant has activity for cardiac Na+ and K+ channels and also for the atrial-selective Kv1.5 channel. Vernakalant (RSD1235) was characterized in animal models to assess efficacy, atrial selectivity, and reduction in side effects.

Originator

Cardiome Pharma Corp. (Canada)

Definition

ChEBI: Vernakalant is an alcohol and a member of phenols.

brand name

Brinavess

VemakalantSupplier

BeiJing Hwrk Chemicals Limted
Tel
0757-86329057 18934348241
Email
sales4.gd@hwrkchemical.com
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
China Nobel Chem Co., Limited
Tel
+86(0)21 60484900
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn